Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5705 - 5712 of 12091 results
TCPA & Consumer Calling Digest – October 2018
October 22, 2018| Article| Viewpoint
TCPA Regulatory Update – FCC Seeks Comments on Several TCPA Provisions
October 22, 2018| Article| Viewpoint
TCPA Class Action Update – Trending: Courts Holding Plaintiffs to Their Word
October 22, 2018| Article| Viewpoint
Costco Settlement Shows CPSC Still Imposing Big Penalties
October 19, 2018| News
ALJ Cheney Holds that IPR Estoppel Does Not Apply to ITC Investigative Staff
October 18, 2018| Blog| Viewpoint
Patent Infringement Claim Involving Complicated Technology May Require Additional Detail in Complaint
October 18, 2018| Blog| Viewpoint
40 Under 40 honorees, up close and personal
October 18, 2018| News
Strategies to Unlock AI's Potential in Health Care, Part 2: FDA’s Approach to Protecting Patients & Promoting Innovation
October 18, 2018| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|